Phage-Based Therapeutics for Ocular Infections

基于噬菌体的眼部感染治疗

基本信息

项目摘要

PROJECT SUMMARY / ABSTRACT Ocular bacterial infections cause a significant number of cases of blindness worldwide. Efforts to prevent damage to delicate ocular tissues during infection rely on swift and proper use of therapeutics to rapidly kill organisms and arrest damaging inflammation. Mainstay antibiotics currently approved for ocular use can kill ocular pathogens. However, given the speed at which these infections can evolve, the emergence of multidrug resistant (MDR) ocular pathogens, the delicate nature of ocular tissue, and the importance of proper visual acuity, halting these infections as soon as possible is critical to patients’ ocular health. Alternative antimicrobial strategies which result in rapid killing of organisms in the eye would provide a significant improvement over that of mainstay antibiotics which allow replication due to their slow activities, or antibiotics that are ineffective due to MDR pathogens. Bacteriophage-based therapeutics have gained traction as a last line experimental strategy for the treatment of patients infected with MDR pathogens. Efficacy testing of phages and, more recently, phage lysins, in treating bacterial infections is not new. However, their use in treating ocular infections of all types in a broad-spectrum regimen in eye infections has not been studied. Our goal is to create a phage lysin cocktail which can be administered to the eye during infection, resulting in rapid killing of those organisms, mitigation of inflammation, and preservation of vision. We hypothesize that because phage lysins rapidly lyse bacteria prior to phage exit, these lysins will rapidly kill bacteria in ocular tissues during infection. Preliminary data demonstrates feasibility and success in phage lysin-mediated killing of S. aureus in the eyes of mice. The next steps are to test the efficacy of phage lysins in killing other ocular bacterial pathogens in experimental models of keratitis and endophthalmitis (Aim 1), and then combine and test phage lysins of different bacteria in a broad-spectrum cocktail in these models against MDR pathogens (Aim 2). A critical barrier to clinical improvements in ocular bacterial infections is the use of mainstay antibiotics that may not kill efficiently enough. We have reported that regardless of the offending pathogen, bacterial replication in the eye triggers acute inflammation in response to an increasing innate immune agonist burden and results in toxin production which leads to tissue damage. These studies will determine whether phage lysins kill ocular pathogens more efficiently than mainstay antibiotics, resulting in improvements in therapeutic outcome. If effective, the next step is to test the phage lysin cocktails with innate pathway-based anti-inflammatory agents, which we are also pursuing. Testing of phage lysins in the treatment of ocular bacterial infections is novel, high-impact, translationally relevant, and will positively influence the ocular infectious disease field by identifying a more effective antimicrobial strategy for treating ocular infections, preventing blindness and benefitting patients afflicted with these infections.
项目总结/摘要 眼部细菌感染在世界范围内导致大量失明病例。努力 在感染期间防止对脆弱的眼组织的损伤依赖于迅速和适当地使用治疗剂, 迅速杀死有机体并阻止破坏性炎症。目前批准用于眼部的主要抗生素 使用可以杀死眼部病原体。然而,考虑到这些感染的发展速度, 多药耐药(MDR)眼部病原体,眼部组织的脆弱性,以及 正确的视力,尽快阻止这些感染对患者的眼睛健康至关重要。替代 导致快速杀死眼睛中的生物体的抗微生物策略将提供显著的 相对于主要抗生素的改进,主要抗生素由于其缓慢的活性而允许复制,或抗生素 因为MDR病原体而无效。 基于噬菌体的治疗方法已经获得牵引力,作为治疗癌症的最后一线实验策略。 治疗感染MDR病原体的患者。抗病毒药物的功效测试,以及最近的噬菌体 溶素用于治疗细菌感染并不新鲜。然而,它们在治疗各种类型的眼部感染中的用途是不确定的。 尚未研究眼感染的广谱治疗方案。我们的目标是创造一种噬菌体溶素鸡尾酒 其可以在感染期间施用于眼睛,导致快速杀死那些生物体,缓解 以及视力的保护。我们假设由于噬菌体溶素快速溶解 在噬菌体离开之前,这些溶素将在感染期间迅速杀死眼组织中的细菌。 初步数据表明噬菌体溶素介导的S.眼睛金黄色 对小鼠下一步是测试噬菌体溶素在杀死其他眼部细菌病原体中的功效, 实验模型的角膜炎和眼内炎(目的1),然后联合收割机和测试噬菌体溶素 在这些模型中,广谱混合物中的不同细菌对抗MDR病原体(目标2)。 眼部细菌感染临床改善的一个关键障碍是使用Mastrial 抗生素可能不能有效地杀死。我们已经报道过,不管是什么病原体, 眼内细菌复制触发急性炎症,以响应增加的先天免疫激动剂 负担并导致毒素产生,从而导致组织损伤。这些研究将确定是否 噬菌体溶素比主流抗生素更有效地杀死眼部病原体,从而改善 治疗效果如果有效的话,下一步是用基于先天途径的噬菌体溶素鸡尾酒来测试。 抗炎药,我们也在研究。噬菌体溶素在眼部疾病治疗中的测试 细菌感染是新的,高影响,预防相关,并将积极影响 通过鉴定治疗眼部感染性疾病的更有效的抗微生物策略 预防失明并使患有这些感染的患者受益。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Roles of CCL2 and CCL3 in intraocular inflammation during Bacillus endophthalmitis.
  • DOI:
    10.1016/j.exer.2022.109213
  • 发表时间:
    2022-11
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Mursalin, Md Huzzatul;Astley, Roger;Coburn, Phillip S.;Miller, Frederick C.;Callegan, Michelle C.
  • 通讯作者:
    Callegan, Michelle C.
C-X-C Chemokines Influence Intraocular Inflammation During Bacillus Endophthalmitis.
  • DOI:
    10.1167/iovs.62.14.14
  • 发表时间:
    2021-11-01
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Mursalin MH;Coburn PS;Miller FC;Livingston ET;Astley R;Callegan MC
  • 通讯作者:
    Callegan MC
Therapeutic potential of Bacillus phage lysin PlyB in ocular infections.
  • DOI:
    10.1128/msphere.00044-23
  • 发表时间:
    2023-08-24
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michelle C Callegan其他文献

Michelle C Callegan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michelle C Callegan', 18)}}的其他基金

Staphylococcus Biology in Ocular Infections
眼部感染中的葡萄球菌生物学
  • 批准号:
    10672933
  • 财政年份:
    2021
  • 资助金额:
    $ 21.1万
  • 项目类别:
Staphylococcus Biology in Ocular Infections
眼部感染中的葡萄球菌生物学
  • 批准号:
    10473723
  • 财政年份:
    2021
  • 资助金额:
    $ 21.1万
  • 项目类别:
Staphylococcus Biology in Ocular Infections
眼部感染中的葡萄球菌生物学
  • 批准号:
    10296009
  • 财政年份:
    2021
  • 资助金额:
    $ 21.1万
  • 项目类别:
Phage-Based Therapeutics for Ocular Infections
基于噬菌体的眼部感染治疗
  • 批准号:
    10039252
  • 财政年份:
    2020
  • 资助金额:
    $ 21.1万
  • 项目类别:
Pathogenic Mechanisms of Bacillus Endophthalmitis
芽孢杆菌眼内炎的致病机制
  • 批准号:
    10178032
  • 财政年份:
    2018
  • 资助金额:
    $ 21.1万
  • 项目类别:
Pathogenic Mechanisms of Bacillus Endophthalmitis
芽孢杆菌眼内炎的致病机制
  • 批准号:
    9759927
  • 财政年份:
    2018
  • 资助金额:
    $ 21.1万
  • 项目类别:
Pathogenic Mechanisms of Bacillus Endophthalmitis
芽孢杆菌眼内炎的致病机制
  • 批准号:
    10428514
  • 财政年份:
    2018
  • 资助金额:
    $ 21.1万
  • 项目类别:
Nanotherapeutics for Ocular Infections
眼部感染的纳米疗法
  • 批准号:
    9341333
  • 财政年份:
    2015
  • 资助金额:
    $ 21.1万
  • 项目类别:
Nanotherapeutics for Ocular Infections
眼部感染的纳米疗法
  • 批准号:
    8985810
  • 财政年份:
    2015
  • 资助金额:
    $ 21.1万
  • 项目类别:
Vision Science Training Program
视觉科学培训计划
  • 批准号:
    10180599
  • 财政年份:
    2014
  • 资助金额:
    $ 21.1万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了